HEMLIBRA is a treatment for hemophilia A with factor VIII inhibitors

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors.

  • Hemophilia A is a bleeding condition people can be born with where a missing or faulty blood clotting factor (factor VIII) prevents blood from clotting normally.
  • HEMLIBRA is a therapeutic antibody that bridges clotting factors to help your blood clot.
  • HEMLIBRA can reduce all bleeds (whether treated or not), and the number of treated bleeding episodes, including joint bleeds, spontaneous bleeds, and target joint bleeds.

HEMLIBRA is not a cure for hemophilia.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Discontinue prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent, and the dose and schedule you should use. HEMLIBRA may cause serious side effects when used with aPCC (FEIBA®), including thrombotic microangiopathy (TMA) and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

How HEMLIBRA is thought to work

HEMLIBRA is thought to bridge activated factor IX (9) and factor X (10) to restore the function of missing activated factor VIII (8) to help your blood clot.

HEMLIBRA in the body

  • Pharmacokinetics is the movement of a drug into, through, and out of the body; it helps healthcare providers understand how long a medicine lasts in the body. The pharmacokinetics of HEMLIBRA were evaluated in both HAVEN 1 and HAVEN 2.
  • After 3 mg/kg injections once weekly for the first 4 weeks, HEMLIBRA levels in the blood increased to approximately 50 μg/mL at week five of the trial. These levels were sustained with once-weekly dosing of 1.5 mg/kg.

Instructions for Use

Step-by-step instructions for administering HEMLIBRA

Clinical Studies

Learn more about the HAVEN 1 and HAVEN 2 clinical trials